These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 1951408)

  • 21. Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.
    Balfour JA; Benfield P
    Pharmacoeconomics; 1996 Aug; 10(2):164-78. PubMed ID: 10163419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic efficacy of intravenous and oral ciprofloxacin in experimental murine infections.
    Nishino T; Obana Y
    Chemotherapy; 1996; 42(2):140-5. PubMed ID: 8697889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Focus on oral ciprofloxacin; clinical and economic considerations.
    Pastel D
    Hosp Pharm; 1989 Oct; 24(10):814-20, 823-6, 842. PubMed ID: 10295899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center.
    Gauthier M; Chevalier I; Sterescu A; Bergeron S; Brunet S; Taddeo D
    Pediatrics; 2004 Oct; 114(4):e469-76. PubMed ID: 15466073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
    Croom KF; Goa KL
    Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections.
    Gaut PL; Carron WC; Ching WT; Meyer RD
    Am J Med; 1989 Nov; 87(5A):169S-175S. PubMed ID: 2686417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of intravenous ciprofloxacin in the treatment of selected infections.
    Abadie-Kemmerly S; Pankey GA
    Am J Med; 1989 Nov; 87(5A):213S-220S. PubMed ID: 2589363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous/oral ciprofloxacin versus intravenous ceftazidime in the treatment of serious gram-negative infections of the skin and skin structure.
    Gentry LO; Koshdel A
    Am J Med; 1989 Nov; 87(5A):132S-135S. PubMed ID: 2686413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of serious infections with intravenous ciprofloxacin.
    Scully BE; Neu HC
    Am J Med; 1987 Apr; 82(4A):369-75. PubMed ID: 3555062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections.
    Paladino JA; Gilliland-Johnson KK; Adelman MH; Cohn SM
    Surg Infect (Larchmt); 2008 Jun; 9(3):325-33. PubMed ID: 18570574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Bacterial infections in liver cirrhosis].
    Papp M; Farkas A; Udvardy M; Tornai I
    Orv Hetil; 2007 Mar; 148(9):387-95. PubMed ID: 17344166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative clinical, microbiologic, and economic audit of the use of oral ciprofloxacin and parenteral antimicrobials.
    Cooke J; Cairns CJ; Tillotson GS; Conner S; Lewin SK; Nicholls J; Tredree RL; Willis JV; Hitchings CR
    Ann Pharmacother; 1993 Jun; 27(6):785-9. PubMed ID: 8329804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.
    Wiseman LR; Balfour JA
    Drugs Aging; 1994 Feb; 4(2):145-73. PubMed ID: 8186542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral ciprofloxacin treatment of infections in geriatric patients.
    Yangco BG; Kenyon VS; Halkias KD; Bogel JA; Toney JF; Chmel H
    Clin Ther; 1989; 11(4):503-10. PubMed ID: 2776166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections.
    Walters DJ; Solomkin JS; Paladino JA
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):551-61. PubMed ID: 10662480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of intravenous ciprofloxacin in the treatment of serious infections. A comparison with ceftazidime.
    Quintero-Perez NP; Andrade-Villaneuva JF; Leon-Garnica G; Bertin-Montano M; Rodriguez-Chagollan JJ; Rodriguez-Noriega E
    Am J Med; 1989 Nov; 87(5A):198S-201S. PubMed ID: 2686424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria.
    Preheim LC; Cuevas TA; Roccaforte JS; Mellencamp MA; Bittner MJ
    Am J Med; 1987 Apr; 82(4A):295-300. PubMed ID: 3555051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RAIN study: a protocol for a randomised controlled trial evaluating efficacy, safety and cost-effectiveness of intravenous-to-oral antibiotic switch therapy in neonates with a probable bacterial infection.
    Keij FM; Kornelisse RF; Hartwig NG; Mauff K; Poley MJ; Allegaert K; Reiss IKM; Tramper-Stranders GA
    BMJ Open; 2019 Jul; 9(7):e026688. PubMed ID: 31289068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative activities of pefloxacin and ciprofloxacin in the treatment of chronic respiratory tract infections.
    Scaglione F; Scamazzo F; Arcidiacono MM; Cogo R; Monzani GP; Fraschini F
    J Chemother; 1995 Apr; 7(2):140-5. PubMed ID: 7666121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.
    Plosker GL; Foster RH; Benfield P
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.